2024-511104-16-00Not yet recruitingPhase 2
Molecular theranostics for metastatic prostate cancer: PSMA, FAPI, or both?
Source: EU CTIS (euclinicaltrials.eu) · Last updated 28 Feb 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Evaluate the lesion-specific expression of prostate-specific membrane antigen (PSMA) and fibroblast activation-protein (FAP) in metastatic prostate cancer
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 10 Feb 2024
- Start date
- 23 Jan 2024
- Lead sponsor
- Turku University Hospital
- Diseases
- Prostate cancer
- EU CT number
- 2024-511104-16-00
- EudraCT number
- 2022-003788-13
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 40
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Other illness
- Medical conditions prohibiting whole-body PET/CT imaging
Other
- Patient is not able to understand the purpose of the study
Who the study is looking for
- Men with histologically confirmed prostate cancer
- Age 50-85 years at baseline
- WHO performance score 0-2
- At least one distant metastasis detected on CT, MRI, bone scintigraphy (BS) or single-photon emission computed tomography (SPECT) imaging
- All previous treatment lines are allowed
- Patient signs informed consent form after receiving written information
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Turku University Hospital | Turku | Finland | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.